Is FDA dissolution database more preferable to product specific FDA BE guidance? [Dissolution / BCS / IVIVC]

posted by Vineeth KE – India, 2019-04-25 13:15 (633 d 16:27 ago) – Posting: # 20229
Views: 1,670

» For a Oral solid dosage form [tablet and suspension], FDA dissolution database is recommending dissolution to be done at 25 degrees whereas, product specific FDA guidance for the same product is mentioning 37 degrees.
»
» Which temperature should i need to adapt and follow for generic development ?

For development purpose, it is advisable to follow 37 degrees, as it mimics in-vivo condition (For oral solid dosage form).

If the drug release is affected by temperature (due to API solubility/Surfactant Solubility in dissolution media/API degradation/gelling of excipients or any other reasons), it is better to consider the worst case scenario (25 or 37degrees).

For submission purpose, we need to evaluate in both the conditions as mentioned in FDA-Dissolution database & FDA-Product specific guidance.

Complete thread:

Activity
 Admin contact
21,303 posts in 4,441 threads, 1,487 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Monday 04:42 CET (Europe/Vienna)

I believe there is no philosophical high-road in science,
with epistemological signposts. No, we are in a jungle
and find our way by trial and error,
building our road behind us as we proceed.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5